account_balance
Investment manager · 13F filer · SEC CIK 1131399
GSK PLC
Reported value$497Mas of Sep 30, 2026
Positions13 0 new, 0 sold out
Top 10 weight98.1%CRSP alone is 29%
FiledNov 536 days after quarter end
Portfolio · as of Sep 30, 2026
Where the money is
New or addedTrimmedHeld
CRSPCrispr Therapeutics AG
29.0%Trimmed −19%
VIRVir Biotechnology Inc
19.2%
WVEWave Life Sciences Inc
13.6%
BNTXBiontech Se
13.2%Trimmed −25%
IDYAIdeaya Biosciences Inc
10.3%
CYTKCytokinetics Inc
4.5%
LYELLyell Immunopharma Inc
3.0%
SPROSpero Therapeutics Inc
2.2%
NKTX1.7%FULC1.3%BCYC1.1%RGNXCRSPCrispr Therapeutics AG
29.0%Trimmed −19%
VIRVir Biotechnology Inc
19.2%
WVEWave Life Sciences Inc
13.6%
BNTXBiontech Se
13.2%Trimmed −25%
IDYAIdeaya Biosciences Inc
10.3%
CYTK4.5%LYEL3.0%SPRO2.2%NKTXBCYCBoxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
CRSP Crispr Therapeutics AG 29.0% Trimmed −19%VIR Vir Biotechnology Inc 19.2% HeldWVE Wave Life Sciences Inc 13.6% HeldBNTX Biontech Se 13.2% Trimmed −25%IDYA Ideaya Biosciences Inc 10.3% HeldCYTK Cytokinetics Inc 4.5% HeldLYEL Lyell Immunopharma Inc 3.0% HeldSPRO Spero Therapeutics Inc 2.2% HeldNKTX Nkarta Inc 1.7% HeldFULC Fulcrum Therapeutics Inc 1.3% HeldBCYC Bicycle Therapeutics PLC 1.1% HeldRGNX Regenxbio Inc 0.4% Held
What changed